Successful Use of Adalimumab for Treating Pyoderma Gangrenosum with Ulcerative Colitis under Corticosteroid-tapering Conditions.
A 52-year-old woman with ulcerative colitis was admitted to our hospital for an ulcerative colitis flare-up under salazosulfapyridine therapy. The symptoms improved with high-dose corticosteroids. After prednisolone was tapered to 10 mg, the frequency of diarrhea increased. The diarrhea was accompanied by joint pain and a skin ulcer with abscess formation, which was diagnosed to be pyoderma gangrenosum. The patient was started on adalimumab. A positive response to the adalimumab therapy was observed after 2 weeks, during which time the ulcerative skin lesion healed completely, however, colonic mucosal healing was achieved at 2 months. Therefore, adalimumab appears to be an effective therapeutic option for patients with ulcerative colitis-associated pyoderma gangrenosum.
Department of Medicine and Molecular Science, Hiroshima University, Japan.
Shintaro
S
Sagami
Yoshitaka
Y
Ueno
Shinji
S
Tanaka
Kenta
K
Nagai
Ryohei
R
Hayashi
Kazuaki
K
Chayama
D000068879:Adalimumab / Q000008:administration & dosage / Q000627:therapeutic use*; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D003093:Colitis, Ulcerative / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage*; D017511:Pyoderma Gangrenosum / Q000188:drug therapy* / Q000209:etiology; D012883:Skin Ulcer / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D012460:Sulfasalazine / Q000008:administration & dosage; D017211:Treatment Failure; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D012460:Sulfasalazine; D011239:Prednisolone; D000068879:Adalimumab